Firdapse approved to treat LEMS patients in Japan
Firdapse (amifampridine) has been approved in Japan to treat people with Lambert-Eaton myasthenic syndrome (LEMS). The therapy will be supplied in the form of oral tablets containing 10 mg of amifampridine, according to Catalyst Pharmaceuticals, the company that holds Firdapse’s licensing rights in North America. In collaboration with…